In June, South Korea’s Ministry of Health and Welfare (MOHW) issued an administrative notice to withdraw the plan to apply the stepped drug pricing reduction on drugs transferred by business restructuring. And it has been three months since the ministry completed collecting the public opinion in August. But the finalized notice has not been disclosed.

When the decision was made, the pharmaceutical industry seemed relieved and also complimented the government for swiftly changing the policy to reflect the public opinion. Daily Pharm also praised the MOHW’s action as an example of a ‘Smart healthcare administration.”

However, the companies, who were relieved about the change and push